| P/E (FY) | — | Sales (TTM) | $160.0M |
| Earnings (TTM) | -$128.6M | ROE | −213.45% |
| Net Margin | −341.47% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 7.64% |
Pacific Biosciences of California designs, develops, and manufactures sequencing solutions for genetically complex problems. It provides sequencing systems and consumable products built on single molecule real-time (SMRT) long-read technology, along with reagent kits for library preparation, binding, and on-instrument sequencing. The company's instruments include the Revio, Vega, and Sequel systems, which conduct, monitor, and analyze single-molecule sequencing.
| Market Cap | $422.4M | Trading Days | 3956 |
| 52W High | 2.73 |
| 52W Low | 1.09 |
| % Off High | −50.18% |
| YTD | −27.27% | 1Y | −17.07% |
| 3Y | −89.69% | 5Y | −95.47% |
| 10Y | −83.21% | Since incept. (ann.) | −14.64% |
Reportable 100%
| Ann. Volatility (1Y) | 86.22% | Ann. Volatility (3Y) | 98.42% |
| Sharpe (1Y) | 0.23 | Sharpe (3Y) | −0.26 |
| Max Drawdown (1Y) | −58.05% | Max Drawdown (3Y) | −93.26% |
| Beta (3Y, vs SPY) | 2.67 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LAB | STANDARD BIOTOOLS INC. | $310.0M | — |
| CTKB | Cytek Biosciences, Inc. | $576.0M | — |
| HBIO | HARVARD BIOSCIENCE INC | $262.8M | — |
| EYPT | EyePoint, Inc. | $1.00B | — |
| QTRX | Quanterix Corp | $164.4M | — |
| NAUT | Nautilus Biotechnology, Inc. | $152.5M | — |
| ASTC | ASTROTECH Corp | $124.9M | — |
| SEER | Seer, Inc. | $117.7M | — |
| ALMR | Alamar Biosciences, Inc. | $1.69B | — |
| RPID | RAPID MICRO BIOSYSTEMS, INC. | $92.0M | — |
| PRPO | Precipio, Inc. | $40.5M | — |
| TXG | 10x Genomics, Inc. | $5.87B | — |
